Aliases & Classifications for Mouth Disease

MalaCards integrated aliases for Mouth Disease:

Name: Mouth Disease 12 15 17
Mouth Diseases 43 71
Mouth Disorders 42

Classifications:



External Ids:

Disease Ontology 12 DOID:403
MeSH 43 D009059
NCIt 49 C3240
SNOMED-CT 67 118938008
UMLS 71 C0026636

Summaries for Mouth Disease

MedlinePlus : 42 Your mouth is one of the most important parts of your body. It has many different functions. It allows you to Take in food and drink Breathe in air Start digestion, with your teeth chewing the food you eat and your salivary glands releasing saliva to help break down the food Speak and sing Show emotion, by smiling or pouting Any problem that affects your mouth can make it hard to eat, drink, or even smile. Some common mouth problems include Cold sores - painful sores on the lips and around the mouth, caused by a virus Canker sores - painful sores in the mouth, caused by bacteria or viruses Thrush - a yeast infection that causes white patches in your mouth Leukoplakia - white patches of excess cell growth on the cheeks, gums or tongue, common in smokers Dry mouth - a lack of enough saliva, caused by some medicines and certain diseases Gum or tooth problems Bad breath Treatment for mouth disorders varies, depending on the problem. If a mouth problem is caused by some other disease, treating that disease can help. It is also important to keep your mouth clean and healthy by brushing, flossing, and not using tobacco.

MalaCards based summary : Mouth Disease, also known as mouth diseases, is related to hand, foot and mouth disease and exanthem, and has symptoms including tinnitus, snoring and halitosis. An important gene associated with Mouth Disease is G3BP1 (G3BP Stress Granule Assembly Factor 1), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Mannitol and Ribavirin have been mentioned in the context of this disorder. Affiliated tissues include mouth, testes and kidney, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Disease Ontology : 12 A gastrointestinal system disease that is located in the mouth.

Related Diseases for Mouth Disease

Diseases related to Mouth Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 540)
# Related Disease Score Top Affiliating Genes
1 hand, foot and mouth disease 35.2 VDR TLR7 TLR4 TLR3 SCARB2 IL6
2 exanthem 32.1 IL6 IL10 IFNG IFNA1 CRP
3 stomatitis 32.1 TLR4 IL6 IL10 IFNG IFNA1 DDX58
4 aseptic meningitis 32.0 SCARB2 IL10 IFNG CRP
5 encephalitis 31.8 TLR3 STAT1 IRF3 IL6 IL10 IFNA1
6 myocarditis 31.8 TLR4 TLR3 IL6 IL10 IFNG IFNA1
7 herpangina 31.8 TP53 TLR7 TLR4 TLR3 IRF3 IL6
8 poliomyelitis 31.7 SCARB2 IL10 IFNG EIF4G1
9 pulmonary edema 31.6 IL13 IL10 CRP
10 dermatitis 31.5 IL6 IL13 IL10 IFNG
11 vaccinia 31.5 TP53 STAT1 IRF3 IL6 IFNA1
12 rhinitis 31.4 TLR4 IL6 IL13 IL10 IFNG
13 viral infectious disease 31.4 TLR7 TLR4 TLR3 STAT1 IRF3 IL6
14 chickenpox 31.4 TLR3 STAT1 IL6 IL10 IFNG IFNA1
15 plague 31.4 TLR4 TLR3 IL6 IL10 DDX58
16 brucellosis 31.4 TLR4 IL6 IL13 IL10 IFNG CRP
17 erythema multiforme 31.3 IL6 IL13 IFNG
18 meningoencephalitis 31.3 TLR3 IL6 IL10 CRP
19 meningitis 31.3 TLR4 IL6 IL13 IL10 IFNG CRP
20 viral encephalitis 31.2 TLR3 IL6 IL10 IFNA1 DDX58
21 aphthous stomatitis 31.2 TLR4 IL6 IL10 IFNG
22 measles 31.2 TLR7 TLR4 TLR3 STAT1 IRF3 IL6
23 skin disease 31.2 VDR TP53 IL6 IL13 IL10 IFNG
24 respiratory failure 31.1 TLR4 IL6 IL13 IL10 CRP
25 hepatitis a 31.1 TLR4 TLR3 IL10 IFNG IFNA1
26 dermatitis, atopic 31.1 TLR4 TLR3 STAT1 IL6 IL13 IL10
27 avian influenza 31.1 IL6 IFNA1 DDX58
28 diarrhea 31.1 TLR4 STAT1 IRF3 IL6 IL13 IL10
29 rabies 31.0 TLR3 STAT1 IRF3 IFNA1 DDX58
30 pancreatitis 31.0 TP53 IL6 IL10 CRP
31 trypanosomiasis 31.0 TLR4 IL6 IL10 IFNG
32 venezuelan equine encephalitis 31.0 STAT1 IFNG IFNA1
33 herpes simplex 31.0 TLR3 STAT1 IRF3 IL6 IFNA1 DDX58
34 japanese encephalitis 31.0 TLR7 TLR3 IFNA1
35 syphilis 31.0 IL6 IFNG CRP
36 chorioretinitis 30.9 IL6 IL10 IFNG
37 chlamydia 30.9 TLR4 IL6 IL10 IFNG CRP
38 endocarditis 30.9 IL6 IL10 IFNG CRP
39 tetanus 30.9 IL6 IL13 IL10 IFNG CRP
40 acute pancreatitis 30.9 TLR4 IL6 IL10 CRP
41 human immunodeficiency virus type 1 30.8 TLR3 STAT1 IRF3 IL10 IFNG
42 immune deficiency disease 30.8 VDR STAT1 IL6 IL13 IL10 IFNG
43 severe acute respiratory syndrome 30.8 STAT1 IRF3 IL6 IL10 IFNG IFNA1
44 influenza 30.8 TLR7 TLR4 TLR3 STAT1 IRF3 IL6
45 bronchopneumonia 30.7 TLR4 IL6 IL10 CRP
46 tick-borne encephalitis 30.7 TLR3 IL10 IFNA1 DDX58
47 acute myocarditis 30.7 TLR3 STAT1 IL10 CRP
48 appendicitis 30.7 TLR4 IL6 IL10 IFNG CRP
49 fasciitis 30.7 TP53 IL6 IFNG IFNA1 CRP
50 cellulitis 30.7 IL6 IL10 IFNG CRP

Graphical network of the top 20 diseases related to Mouth Disease:



Diseases related to Mouth Disease

Symptoms & Phenotypes for Mouth Disease

UMLS symptoms related to Mouth Disease:


tinnitus, snoring, halitosis, sore throat, coughing, vertigo/dizziness, equilibration disorder, oral manifestations

GenomeRNAi Phenotypes related to Mouth Disease according to GeneCards Suite gene sharing:

26 (show all 19)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-113 9.62 TLR4
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-114 9.62 EIF4G1 TLR4
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-128 9.62 IL10
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-132 9.62 IL10
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-133 9.62 EIF4G1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 9.62 EIF4G1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-169 9.62 TLR4
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.62 IL10
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.62 IL10
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.62 CRP
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-185 9.62 EIF4G1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-25 9.62 IL10
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.62 IL10
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-38 9.62 EIF4G1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 9.62 CRP
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.62 CRP
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-8 9.62 EIF4G1
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-80 9.62 IL10
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.62 CRP

MGI Mouse Phenotypes related to Mouth Disease:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.4 DDX58 IFNG IL10 IL13 IL17F IL6
2 immune system MP:0005387 10.4 CRP DDX58 IFNG IL10 IL13 IL17F
3 cellular MP:0005384 10.39 DDX58 G3BP1 IFNG IL10 IL13 IL6
4 homeostasis/metabolism MP:0005376 10.39 CRP DDX58 IFNG IL10 IL13 IL6
5 cardiovascular system MP:0005385 10.36 CRP G3BP1 IFNG IL10 IL6 NOTCH1
6 growth/size/body region MP:0005378 10.36 DDX58 G3BP1 IFNG IL10 IL13 IL17F
7 mortality/aging MP:0010768 10.34 DDX58 G3BP1 G3BP2 IFNG IL10 IL13
8 digestive/alimentary MP:0005381 10.3 DDX58 IFNG IL10 IL13 IL17F IL6
9 integument MP:0010771 10.13 IFNG IL10 IL13 IL6 NOTCH1 STAT1
10 craniofacial MP:0005382 10.11 G3BP1 IFNG IL10 IL17F NOTCH1 TP53
11 muscle MP:0005369 10.1 IFNG IL10 IL13 IL6 NOTCH1 STAT1
12 nervous system MP:0003631 10.1 G3BP1 IFNG IL10 IL13 IL6 NOTCH1
13 liver/biliary system MP:0005370 10.06 DDX58 IFNG IL10 IL6 NOTCH1 STAT1
14 neoplasm MP:0002006 10.02 DDX58 IFNG IL10 IL6 NOTCH1 STAT1
15 hearing/vestibular/ear MP:0005377 10.01 IL13 NOTCH1 SCARB2 TLR4 TP53 VDR
16 respiratory system MP:0005388 9.93 G3BP1 IFNG IL10 IL13 IL17F IL6
17 renal/urinary system MP:0005367 9.86 IFNG IL6 NOTCH1 SCARB2 TLR4 TLR7
18 skeleton MP:0005390 9.7 IFNG IL10 IL13 IL17F IL6 NOTCH1
19 vision/eye MP:0005391 9.28 G3BP1 IFNG IL10 IL6 IRF3 NOTCH1

Drugs & Therapeutics for Mouth Disease

Drugs for Mouth Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
2
Ribavirin Approved Phase 4 36791-04-5 37542
3 Immunoglobulins, Intravenous Phase 4
4 Antimetabolites Phase 4
5 Antibodies, Blocking Phase 4
6 Antibodies Phase 4
7 Immunoglobulins Phase 4
8 Vaccines Phase 4
9 Immunologic Factors Phase 4
10
Chlorhexidine Approved, Vet_approved Phase 3 55-56-1 9552079 2713
11
Hydroxychloroquine Approved Phase 2, Phase 3 118-42-3 3652
12 Chlorhexidine gluconate Phase 3
13 Anti-Infective Agents, Local Phase 3
14 Dermatologic Agents Phase 3
15 Disinfectants Phase 3
16 Antiviral Agents Phase 2, Phase 3
17 Anti-Infective Agents Phase 2, Phase 3
18 Antirheumatic Agents Phase 2, Phase 3
19 Antiprotozoal Agents Phase 2, Phase 3
20 Antiparasitic Agents Phase 2, Phase 3
21 Antimalarials Phase 2, Phase 3
22
Ibuprofen Approved Phase 2 15687-27-1 3672
23
Acetaminophen Approved Phase 2 103-90-2 1983
24
Sucralfate Approved Phase 2 54182-58-0
25
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
26
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 2 7487-88-9 24083
27
Nicotine Approved Phase 1, Phase 2 54-11-5 942 89594
28
Aluminum sulfate Approved Phase 2 10043-01-3
29
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
30
Lobeline Investigational Phase 2 90-69-7
31 Anti-Inflammatory Agents Phase 2
32 Analgesics, Non-Narcotic Phase 2
33 Antipyretics Phase 2
34 Cyclooxygenase Inhibitors Phase 2
35 Anti-Inflammatory Agents, Non-Steroidal Phase 2
36 Gastrointestinal Agents Phase 2
37 Hormones Phase 2
38 Antacids Phase 2
39 Anti-Ulcer Agents Phase 2
40 Analgesics Phase 2
41 Anesthetics Phase 2
42 Retinol palmitate Phase 2
43 retinol Phase 2
44 Anti-Arrhythmia Agents Phase 2
45 Tocolytic Agents Phase 2
46 Anticonvulsants Phase 2
47 Calcium, Dietary Phase 2
48 calcium channel blockers Phase 2
49 Adjuvants, Immunologic Phase 2
50 Respiratory System Agents Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 90)
# Name Status NCT ID Phase Drugs
1 Safety, Three Batches Consistency and Immunity Duration of the Post-marketing Inactivated Enterovirus Type 71 (EV71) Vaccine in Children Aged 6-71 Months Unknown status NCT02889497 Phase 4
2 The Safety and Immunogenicity of Enterovirus Type 71 Inactivated Vaccine (Human Diploid Cell) With Two Measles Attenuated Live Vaccine and Live Attenuated Japanese Encephalitis Vaccine at the Same Time Point in Infants (8-month-old) Unknown status NCT03296410 Phase 4
3 The Safety, Immune Persistence and Consistency of Inactivated Enterovirus 71 Vaccine (Human Diploid Cell, KMB-17) Unknown status NCT02999828 Phase 4
4 Effect and Safety of Xiao'er Jiebiao Oral Liquid in Combination With Standard Treatment on Hand-foot-mouth Disease in Pediatric Patients Completed NCT02328651 Phase 4 Ribavirin plus Xiao'er jiebiao oral liquid;Ribavirin
5 A Opened,Randomized and Controlled Trial to Evaluate the Immunity and Safety of Sequential Vaccination of Two Different Commercial EV71 Inactived Vaccines in Healthy Infants Aged 6-35 Months Completed NCT03873740 Phase 4
6 A Phase IV Open-labelled, Single-centered, Stratified-randomized Clinical Trial in Zhejiang Province to Evaluate the Safety and Immunogenicity of EV71 Vaccine Developed by Sinovac Biotech Co., Ltd. Completed NCT03278132 Phase 4
7 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Recombinant Hepatitis B Vaccine/Group A Meningococcal Polysaccharide Vaccine Completed NCT03274102 Phase 4
8 Effectiveness and Safety of Inactivated EV71 Vaccine (Human Diploid Cell) in 6-71 Months Children: an Open-label Controlled Phase Ⅳ Clinical Study Completed NCT03001986 Phase 4
9 Peri-implantitis - Regenerative Treatment With Enamel Matrix Derivative (EMD). Clinical Effects, Microbial Profiles and Molecular Mechanisms. A Randomised Controlled Pilot Study. Completed NCT02500654 Phase 4
10 Multiple Centers, Randomized, and Control Trail on the Immunogenicity and Safety of the Simultaneously Vaccination of Inactivated Enterovirus 71 Vaccine (EV71) and Seasonal Influenza Vaccine(SIV) Recruiting NCT04133584 Phase 4
11 A Randomized, Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Measles, Mumps, and Rubella Combined Live Attenuated Vaccine/ Encephalitis Live Attenuated Vaccine Recruiting NCT04111432 Phase 4
12 Study on Immunogenicity of Inactivated Enterovirus 71 (EV71) Vaccine (Human Diploid Cell, KMB-17) in Large-scale Healthy Children in China Active, not recruiting NCT03240744 Phase 4
13 Phase Ⅳ Clinical Trial, to Evaluate the Efficacy of the Enterovirus 71 (EV71) Inactivated Vaccine and Its Correlation With EV71 Antibody Level Active, not recruiting NCT03903926 Phase 4
14 A Phase IV Clinical Trial for Efficacy Evaluation for Inactivated Vaccine (Vero Cell) Against EV71: A Multicenter, Case-control Study. Enrolling by invitation NCT03582761 Phase 4
15 Three Batches Consistency, Immunity Duration and Safety of Inactivated Enterovirus 71 Vaccine Post-marketing Among Children Aged 6-35 Months in China Not yet recruiting NCT03893747 Phase 4
16 A Comparison of Three Different Modalities in Improving Oral Hygiene in Adult Orthodontic Patients - A Randomized Controlled Trial Not yet recruiting NCT04386421 Phase 4 Plaque disclosing tablets
17 A Multicentered, Double - Blind, Randomized, and Placebo - Controlled Clinical Trial With Inactivated Enterovirus Type 71 (EV71) Vaccines Completed NCT01507857 Phase 3
18 A Multiple-center Randomized Double-blind Placebo-controlled Phase 3 Clinical Trial to Assess the Efficacy and Safety of an Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Aged 6-35 Months Completed NCT01508247 Phase 3
19 Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71 (EV71) Vaccine: A Double-blind, Randomized and Controlled Trial Completed NCT01636245 Phase 3
20 A Phase III Clinical Trial With Randomized, Double-blinded, Controlled Design as Well as Bridging Design to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Children Aged 36-71 Months Completed NCT03909074 Phase 3
21 Multi-Center Phase 3 Trial of Chlorhexidine Gluconate Chip for the Use in Subjects With Peri-Implantitis. Completed NCT02080403 Phase 3 2.5 mg Chlorhexidine gluconate chip
22 A Phase III Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants and Children Completed NCT01569581 Phase 3
23 Treatment of Covid-19 With Favipiravir Versus Hydroxychloroquine: a Randomized Comparator Trial Not yet recruiting NCT04387760 Phase 2, Phase 3 Hydroxychloroquine;Favipiravir
24 Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial Unknown status NCT03241030 Phase 2 Sucralfate;Acetaminophen;Ibuprofen
25 An Open-Label, Dose-Finding, Phase II Study to Evaluate the Immunogenicity and Safety of the Bioreactor-generated EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 2 to 35 Months Old Unknown status NCT03268083 Phase 2
26 A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Chemotherapy and Radiotherapy Unknown status NCT01247246 Phase 2 SCV-07;Placebo
27 Periapical Bone Healing After Apicectomy With and Without Retrograde Root Filling Unknown status NCT00228280 Phase 1, Phase 2
28 A Phase II Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Infants Completed NCT01512706 Phase 2
29 A Randomized, Placebo-controlled, Double-blind Trial of Intravenous Magnesium Sulfate for the Management of Severe Hand, Foot and Mouth Disease With Autonomic Nervous System Dysregulation in Vietnamese Children. Completed NCT01940250 Phase 2 Magnesium Sulphate;Sterile water
30 Phase II, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study of the Effects of RK-0202 on Oral Mucositis in Patients Receiving Radiation Therapy for Tumors of the Oral Cavity, Oropharynx, Nasopharynx, Salivary Glands or Supraglottic Region Completed NCT00230191 Phase 2 RK-0202
31 A Phase II Randomized Double Blind Placebo Controlled Trial to Assess Safety and Efficacy of Velafermin for Prevention of Oral Mucositis in Hematologic Cancer Patients Receiving Autologous Stem Cell Transplant Completed NCT00323518 Phase 2 velafermin;placebo
32 A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of CG53135-05 Administered Intravenously as a Single Dose for the Prevention of Oral Mucositis in Patients Receiving Autologous Hematopoietic Stem Cell Transplant Completed NCT00104065 Phase 2 CG53135-05, velafermin
33 An Open-label, Dose-finding, Phase II Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Pediatric Subjects Aged 3 to 6 Years and 6 to 35 Months Old Completed NCT02777411 Phase 2
34 A Phase II Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants Completed NCT01399853 Phase 2
35 Evaluation of the Clinical Effects of Tooth Powder on Plaque Induced Gingivitis Completed NCT01902095 Phase 2
36 A Booster Dose of Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children Completed NCT01734408 Phase 2
37 Treatment of Smokeless Tobacco Users Completed NCT00218270 Phase 2 Tobacco free snuff
38 Treatment of Smokeless Tobacco Users: Use of Nicotine Replacement Products to Reduce Smokeless Tobacco Use Completed NCT00218244 Phase 1, Phase 2
39 An Adaptive Phase 2 Randomized Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Multiple LOU064 Doses in Patients With Moderate to Severe Sjögren's Syndrome (LOUiSSe) Recruiting NCT04035668 Phase 2 LOU064;Placebo
40 Intraoral Grafting of Ex Vivo Produced Oral Mucosal Composites Unknown status NCT00000111 Phase 1
41 Phase I, Double Blind, Randomized, Placebo-controlled, Dose Escalation Study to Assess the Safety and Immunogenicity of a Prophylactic Vaccine Against Enterovirus Infection in Healthy Adults Completed NCT01376479 Phase 1
42 A Phase Ia Clinical Trial for Inactivated Vaccine(Vero Cell) Against EV71 in Chinese Healthy Young Adults and Children Completed NCT01267903 Phase 1
43 A Blind, Randomized and Placebo-controlled Clinical Trial With Inactivated Enterovirus Type 71 Vaccines in Healthy Children. Completed NCT01273246 Phase 1
44 A Phase Ib Clinical Trial for Inactivated Vaccine (Vero Cell) Against EV71 in Chinese Children and Infants Completed NCT01313715 Phase 1
45 A Phase I Clinical Trial for Inactivated Enterovirus Type 71 Vaccine (Human Diploid Cell, KMB-17 Cell) in Chinese Adults, Children and Infants Completed NCT01391494 Phase 1
46 Evaluation of Polarized Reflectance Spectroscopy for Detection of High-risk Oral Lesions Completed NCT01604759 Phase 1
47 A Randomized, Double-blind, Placebo-controlled, Phase 1 Clinical Trial to Investigate the Safety and Immunogenicity of CJ-40010 After Administration in Healthy Subjects Recruiting NCT04182932 Phase 1
48 A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Study to Evaluate the Tolerance and Pharmacokinetics of Suramin Sodium in Healthy Chinese Adults Recruiting NCT03804749 Phase 1 suramin sodium
49 Validation and Dosimetry Study of [18F]-FBA-A20FMDV2 PET Ligand for Alpha(V)beta6 in Healthy Subjects and in the Lungs of Idiopathic Pulmonary Fibrosis (IPF) Subjects (PETAL Study) Terminated NCT02052297 Phase 1
50 A Multi-Center Clinical Trial To Evaluate Chinese Herbal Medicines in the Treatment of Severe Hand-foot-mouth Disease Unknown status NCT01145664 Herbal concentrate-granules plus western therapy;Reduning Injection plus western therapy;Western therapy

Search NIH Clinical Center for Mouth Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Lidocaine
LIDOCAINE HCL PWDR
Lidocaine Hydrochloride
LIDOCAINE PWDR

Cochrane evidence based reviews: mouth diseases

Genetic Tests for Mouth Disease

Anatomical Context for Mouth Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Mouth Disease:

19
Mouth

MalaCards organs/tissues related to Mouth Disease:

40
Testes, Kidney, T Cells, Tongue, Salivary Gland, B Cells, Skin

Publications for Mouth Disease

Articles related to Mouth Disease:

(show top 50) (show all 9581)
# Title Authors PMID Year
1
COVID-19: a novel coronavirus and a novel challenge for oral healthcare. 42
32382932 2020
2
Radiotherapy-induced oral morbidities in head and neck cancer patients. 42
32378765 2020
3
Can Teledentistry Improve the Monitoring of Patients during the Covid-19 Dissemination? A Descriptive Pilot Study. 42
32414126 2020
4
Enterovirus 71 induces neural cell apoptosis and autophagy through promoting ACOX1 downregulation and ROS generation. 61
32434419 2020
5
Exosomes cloak the virion to transmit Enterovirus 71 non-lytically. 61
31885311 2020
6
Epitope Peptide Amphiphile-Based Nanofiber as an Effective Vaccine for Viral Infectious Diseases. 61
32331099 2020
7
Transboundary Animal Diseases (TADs) affecting domestic and wild African ungulates: African swine fever, foot and mouth disease, Rift Valley fever (1996-2018). 61
32311588 2020
8
A new implication of quasispecies dynamics: Broad virus diversification in absence of external perturbations. 61
32165244 2020
9
Quantifying the risk of hand, foot, and mouth disease (HFMD) attributable to meteorological factors in East China: A time series modelling study. 61
32361359 2020
10
Reduction of foot-and-mouth disease virus transmission in cattle vaccinated one or two weeks before challenge using a commercial polyvalent vaccine. 61
32368734 2020
11
Virological investigation of genetic variation of enterovirus type 71 in hand, foot and mouth disease. 61
32537012 2020
12
Capsid proteins of foot-and-mouth disease virus interact with TLR2 and CD14 to induce cytokine production. 61
32333963 2020
13
Soluble FMDV VP1 proteins fused with calreticulin expressed in Escherichia coli under the assist of trigger factor16 (Tf16) formed into high immunogenic polymers. 61
31739054 2020
14
Acarbose, as a potential drug, effectively blocked the dynamic metastasis of EV71 from the intestine to the whole body. 61
32004757 2020
15
Development and validation of a solid-phase competition ELISA based on virus-like particles of foot-and-mouth disease virus serotype A for antibody detection. 61
32350612 2020
16
Molecular characterisation of foot-and-mouth disease viruses circulating in Ethiopia between 2008 and 2019. 61
32574400 2020
17
Development and serology based efficacy assessment of a trivalent foot-and-mouth disease vaccine. 61
32535015 2020
18
Foot-and-mouth disease virus induces PERK mediated autophagy to suppress antiviral interferon response. 61
32482793 2020
19
Enhanced protective immune response of foot-and-mouth disease vaccine through DNA-loaded virus-like particles. 61
32165331 2020
20
Prevalence and Management of Severe Hand, Foot, and Mouth Disease in Xiangyang, China from 2008-2013. 61
32543714 2020
21
Influence of temperature and humidity on hand, foot, and mouth disease in Guangzhou, 2013-2017. 61
32527174 2020
22
Vitamin D receptor gene methylation in patients with hand, foot, and mouth disease caused by enterovirus 71. 61
32556549 2020
23
Immunomodulatory effects of platelets on the severity of hand, foot, and mouth disease infected with enterovirus 71. 61
32516798 2020
24
Assessing the vaccine effectiveness for hand, foot, and mouth disease in Guangzhou, China: a time-series analysis. 61
32530733 2020
25
Temperature and hand, foot and mouth disease in California: An exploratory analysis of emergency department visits by season, 2005-2013. 61
32278924 2020
26
The Epidemiological and Clinical Characteristics of Hand, Foot, and Mouth Disease in Hangzhou, China, 2016 to 2018. 61
32146823 2020
27
Seasonal Distribution and Meteorological Factors Associated with Hand, Foot, and Mouth Disease among Children in Xi'an, Northwestern China. 61
32157992 2020
28
Effect of heat-clearing and detoxifying Chinese medicines combined with conventional therapy on mild hand, foot, and mouth disease with fever: An individual patient data meta-analysis. 61
32501994 2020
29
Cellular Vimentin Interacts with Foot-and-Mouth Disease Virus Nonstructural Protein 3A and Negatively Modulates Viral Replication. 61
32493819 2020
30
Spatiotemporal analyses of foot and mouth disease outbreaks in cattle farms in Chiang Mai and Lamphun, Thailand. 61
32487166 2020
31
Baculovirus AcMNPV induces type I interferons and NK/NKT cells-mediated protection against foot-and-mouth disease virus in mice. 61
32574690 2020
32
Impairment of the DeISGylation Activity of Foot-and-Mouth Disease Virus Lpro Causes Attenuation In Vitro and In Vivo. 61
32295921 2020
33
Application of median lethal concentration (LC50) of pathogenic microorganisms and their antigens in vaccine development. 61
32539814 2020
34
Livestock and Poultry Production in Nepal and Current Status of Vaccine Development. 61
32575369 2020
35
A temperature-dependent translation defect caused by IRES mutation attenuates foot-and-mouth disease virus: Implications for rational vaccine design. 61
32493820 2020
36
Transcriptome sequencing analysis of SH-SY5Y cells infected with EV71 reveals the potential neuropathic mechanisms. 61
32220619 2020
37
Differences in microbiome and virome between cattle and horses in the same farm. 61
32054207 2020
38
Acute enterovirus infections significantly alter host cellular DNA methylation status. 61
31927072 2020
39
Muscle destruction caused by coxsackievirus A10 in gerbils: construction of a novel animal model for antiviral evaluation. 61
32553610 2020
40
Short-term effects of meteorological factors, air pollution, and sunspot on childhood hand, foot, and mouth disease in Tianjin, China: a new time series regression, 2014-2018. 61
32577970 2020
41
The modification effect of the diurnal temperature range on the exposure-response relationship between temperature and pediatric hand, foot and mouth disease. 61
32208268 2020
42
The Function and Mechanism of Enterovirus 71 (EV71) 3C Protease. 61
32556480 2020
43
Inhibition of Enterovirus 71 by Selenium Nanoparticles Loaded with siRNA through Bax Signaling Pathways. 61
32548434 2020
44
Spatial and temporal distribution of foot and mouth disease outbreaks in Amhara region of Ethiopia in the period 1999 to 2016. 61
32517750 2020
45
Development and validation of a simplified serotyping ELISA based on monoclonal antibodies for the diagnosis of foot-and-mouth disease virus serotypes O, A, C and Asia 1. 61
32530134 2020
46
Corrigendum to "Development and evaluation of silver amplification immunochromatography kit for foot-and-mouth disease virus antigen detection" [J. Virol. Methods 275C (2019) 113736]. 61
32418753 2020
47
Probe-based real-time reverse transcription loop-mediated isothermal amplification (RRT-LAMP) assay for rapid and specific detection of foot-and-mouth disease virus. 61
32524762 2020
48
Foot and mouth disease in a wide range of wild hosts: a potential constraint in disease control efforts worldwide particularly in disease-endemic settings. 61
32504589 2020
49
Evidence of Combined Effect of Amino Acid Substitutions within G-H and B-C Loops of VP1 Conferring Serological Heterogeneity in Foot-and-Mouth Disease Virus Serotype A. 61
32543041 2020
50
A novel particulate delivery system based on antigen-Zn2+ coordination interactions enhances stability and cellular immune response of inactivated foot and mouth disease virus. 61
32539415 2020

Variations for Mouth Disease

Expression for Mouth Disease

Search GEO for disease gene expression data for Mouth Disease.

Pathways for Mouth Disease

Pathways related to Mouth Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 57)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.02 TP53 TLR7 TLR4 TLR3 STAT1 IRF3
2
Show member pathways
13.56 TP53 STAT1 IL6 IL13 IL10 IFNG
3
Show member pathways
13.44 TP53 TLR7 TLR4 TLR3 STAT1 IL6
4
Show member pathways
13.36 TP53 STAT1 IRF3 IL6 IL17F IL13
5
Show member pathways
13.01 TP53 TLR4 TLR3 STAT1 NOTCH1 IRF3
6
Show member pathways
12.99 TP53 TLR4 TLR3 STAT1 IRF3 IL6
7
Show member pathways
12.89 STAT1 IL6 IL13 IL10 IFNG IFNA1
8 12.88 TP53 STAT1 NOTCH1 IL6 IL13 IFNG
9
Show member pathways
12.88 TP53 TLR7 TLR4 TLR3 STAT1 IRF3
10 12.83 TP53 TLR3 STAT1 IRF3 IL6 IFNG
11
Show member pathways
12.76 TLR7 TLR4 TLR3 STAT1 IRF3 IL6
12
Show member pathways
12.64 TLR4 STAT1 IL6 IL10 IFNG
13
Show member pathways
12.64 TP53 STAT1 IL6 IL17F IL10 IFNG
14
Show member pathways
12.6 TLR3 IRF3 IL6 IFNA1 DDX58
15
Show member pathways
12.6 TLR4 STAT1 NOTCH1 IL6 IL17F IL13
16
Show member pathways
12.59 STAT1 IRF3 IFNG IFNA1 EIF4G1 DDX58
17
Show member pathways
12.56 TP53 TLR7 TLR4 TLR3 STAT1 IRF3
18 12.52 TLR7 TLR3 STAT1 IRF3 IL10 IFNG
19
Show member pathways
12.51 STAT1 IL6 IL13 IL10 IFNG IFNA1
20
Show member pathways
12.36 TP53 TLR4 TLR3 STAT1 IRF3 IL6
21
Show member pathways
12.35 IL6 IL17F IL13 IFNG
22
Show member pathways
12.34 TP53 IL6 IFNG CRP
23
Show member pathways
12.33 TLR7 TLR4 TLR3 IRF3 IL6
24 12.3 TLR4 STAT1 IRF3 IL6 IFNA1
25
Show member pathways
12.28 TLR4 STAT1 IL10 IFNG
26
Show member pathways
12.26 TLR4 TLR3 STAT1 IFNG IFNA1
27
Show member pathways
12.24 TLR7 TLR4 STAT1 IL6 IFNG
28
Show member pathways
12.24 TP53 STAT1 IRF3 IL6 IL13 IL10
29 12.17 VDR TLR4 STAT1 IL6 IL10 IFNG
30 12.08 TP53 TLR7 TLR4 TLR3 STAT1 IL6
31
Show member pathways
12.07 TP53 TLR7 TLR4 TLR3 STAT1 IL13
32 12.06 TLR4 IRF3 IL6 IL10
33 12.06 TP53 TLR4 IL6 IFNG
34 12.04 NOTCH1 IL6 IL10 IFNG
35 12.01 TP53 STAT1 IL6 IL17F IL13 IL10
36 11.98 TLR4 IL6 IL10 IFNG
37 11.92 STAT1 IL6 IFNG IFNA1
38 11.87 TP53 STAT1 IL6 IL13 IFNG
39 11.84 TLR4 IRF3 IL6 IL10
40
Show member pathways
11.83 STAT1 IL6 CRP
41 11.83 TLR7 TLR4 TLR3
42 11.82 TLR7 IL6 IL10 IFNG
43 11.8 IL13 IL10 IFNG
44 11.76 TLR4 SCARB2 NOTCH1
45 11.6 TLR4 IL6 IL10 IFNG
46 11.59 TP53 IL6 IFNG
47 11.57 IL6 IL13 IL10
48 11.56 NOTCH1 IL13 IL10 IFNG
49 11.53 VDR IL6 IFNG
50
Show member pathways
11.46 TLR7 TLR4 TLR3 STAT1 IL6 IL17F

GO Terms for Mouth Disease

Cellular components related to Mouth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endosome membrane GO:0010008 9.46 TLR7 TLR4 TLR3 SCARB2
2 cytoplasmic stress granule GO:0010494 9.13 G3BP2 G3BP1 EIF4G1
3 receptor complex GO:0043235 8.92 VDR TLR7 TLR4 NOTCH1

Biological processes related to Mouth Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 10.21 TLR7 TLR4 TLR3 IRF3 G3BP2 G3BP1
2 negative regulation of transcription by RNA polymerase II GO:0000122 10.19 VDR TP53 STAT1 NOTCH1 IRF3 IFNG
3 positive regulation of transcription, DNA-templated GO:0045893 10.16 TP53 STAT1 NOTCH1 IRF3 IL6 IL10
4 immune response GO:0006955 10.11 TLR7 TLR4 NOTCH1 IL6 IL13 IL10
5 innate immune response GO:0045087 10.11 TLR7 TLR4 TLR3 IRF3 G3BP2 G3BP1
6 negative regulation of cell proliferation GO:0008285 10.1 VDR TP53 NOTCH1 IL6 IL10
7 inflammatory response GO:0006954 10.07 TLR7 TLR4 TLR3 IL6 IL17F IL13
8 viral process GO:0016032 10.03 TP53 STAT1 SCARB2 IRF3 G3BP2 G3BP1
9 cellular response to lipopolysaccharide GO:0071222 10.01 VDR TLR4 IRF3 IL6 IL10
10 response to lipopolysaccharide GO:0032496 10 TLR4 NOTCH1 IRF3 IL13 IL10
11 positive regulation of inflammatory response GO:0050729 9.94 TLR7 TLR4 TLR3 IFNG
12 cellular response to mechanical stimulus GO:0071260 9.93 TLR7 TLR4 TLR3 IL13
13 interferon-gamma-mediated signaling pathway GO:0060333 9.92 TP53 STAT1 IRF3 IFNG
14 cytokine-mediated signaling pathway GO:0019221 9.91 TP53 STAT1 IL6 IL17F IL13 IL10
15 positive regulation of transcription by RNA polymerase II GO:0045944 9.9 VDR TP53 TLR4 TLR3 STAT1 NOTCH1
16 Ras protein signal transduction GO:0007265 9.89 TP53 G3BP2 G3BP1
17 humoral immune response GO:0006959 9.89 NOTCH1 IL6 IFNG IFNA1
18 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.88 IL6 IL13 IFNG
19 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.88 TLR7 TLR4 TLR3
20 type I interferon signaling pathway GO:0060337 9.88 STAT1 IRF3 IFNA1
21 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.87 TLR7 TLR4 TLR3
22 positive regulation of smooth muscle cell proliferation GO:0048661 9.87 STAT1 IL6 IL13
23 toll-like receptor signaling pathway GO:0002224 9.85 TLR7 TLR4 TLR3
24 positive regulation of cytokine secretion GO:0050715 9.85 IRF3 IL10 IFNG
25 positive regulation of JAK-STAT cascade GO:0046427 9.85 NOTCH1 IL6 IL10
26 positive regulation of interleukin-6 secretion GO:2000778 9.85 TLR4 IL17F IFNG DDX58
27 TRIF-dependent toll-like receptor signaling pathway GO:0035666 9.84 TLR4 TLR3 IRF3
28 response to exogenous dsRNA GO:0043330 9.84 TLR3 IRF3 IFNA1 DDX58
29 positive regulation of interleukin-12 production GO:0032735 9.83 TLR4 TLR3 IFNG
30 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.82 TLR4 IL6 IL17F
31 necroptotic process GO:0070266 9.81 TP53 TLR4 TLR3
32 positive regulation of macrophage activation GO:0043032 9.8 TLR4 IL13 IL10
33 cellular response to exogenous dsRNA GO:0071360 9.8 TLR3 IRF3 DDX58
34 microglial cell activation GO:0001774 9.8 TLR7 TLR3 IL13 IFNG
35 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.78 TLR4 STAT1 IFNG
36 positive regulation of interleukin-8 production GO:0032757 9.78 TLR7 TLR4 TLR3 DDX58
37 I-kappaB phosphorylation GO:0007252 9.76 TLR7 TLR4 TLR3
38 positive regulation of interferon-beta production GO:0032728 9.76 TLR4 TLR3 IRF3 DDX58
39 positive regulation of MHC class II biosynthetic process GO:0045348 9.75 TLR4 IL10 IFNG
40 positive regulation of interferon-beta biosynthetic process GO:0045359 9.73 TLR7 TLR4 TLR3
41 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.72 TP53 IL6
42 positive regulation of interleukin-6 production GO:0032755 9.72 TLR7 TLR4 TLR3 IL6 DDX58
43 negative regulation of lipid storage GO:0010888 9.71 IL6 CRP
44 positive regulation of chemokine production GO:0032722 9.71 TLR7 TLR4 TLR3 IL6
45 cytoplasmic sequestering of NF-kappaB GO:0007253 9.7 IL10 G3BP2
46 negative regulation of MyD88-independent toll-like receptor signaling pathway GO:0034128 9.69 TLR4 TLR3
47 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.69 TP53 NOTCH1
48 detection of virus GO:0009597 9.68 TLR3 DDX58
49 positive regulation of interferon-alpha biosynthetic process GO:0045356 9.68 TLR7 TLR3
50 positive regulation of stress granule assembly GO:0062029 9.66 G3BP2 G3BP1

Molecular functions related to Mouth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.93 VDR TP53 TLR7 TLR4 TLR3 STAT1
2 identical protein binding GO:0042802 9.86 TP53 TLR4 TLR3 STAT1 IRF3 EIF4G1
3 transmembrane signaling receptor activity GO:0004888 9.72 TLR7 TLR4 TLR3 SCARB2 NOTCH1
4 signaling receptor activity GO:0038023 9.71 VDR TLR4 TLR3 NOTCH1
5 double-stranded RNA binding GO:0003725 9.54 TLR7 TLR3 DDX58
6 cytokine receptor binding GO:0005126 9.33 IL17F IL13 IFNA1
7 cytokine activity GO:0005125 9.1 IL6 IL17F IL13 IL10 IFNG IFNA1

Sources for Mouth Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....